|Videos|June 5, 2020

Hydroxychloroquine & COVID 19: Is It a Clinical "Bear Market" for the Drug?

Author(s)Contagion&reg Editorial Staff

Jason Pogue, PharmD, BCPS, BCIDP, answers questions about the emerging picture for hydroxychloroquine.

Segment Description: Jason Pogue, PharmD, BCPS, BCIDP, clinical pharmacist and professor in infectious diseases at the University of Michigan College of Pharmacy, speaks with Contagion about the emerging picture for hydroxychloroquine, a now-controversial drug which made headlines after showing promise in the lab against SARS-CoV-2.

The debate has been complicated in recent days, after The New England Journal of Medicine and The Lancet had authors issue retractions of articles based on a potentially faulty data source. The contested articles came from a database which cannot be verified. The results also showed what some view as an unrealistic level of harm from the drug, even among hydroxychloroquine skeptics.

A different publication, on use of the drug for out-patient prophylaxis, has offered less contested insight.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

November 5th, 2026

Half of Long COVID Patients Substantially Improve Within 3 years

Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute infection and more than a quarter had completely remitted, in a large prospective cohort study.

October 22nd, 2026

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE

In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.

November 2nd, 2026

Washington State Reports First US Avian Influenza Death of 2026

A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.

November 2nd, 2026

FDA Approves Voceryq, First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis

Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.

November 2nd, 2026

Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37

Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.

October 30th, 2026

Measles Update: October 30, 2026

The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.

October 29th, 2026

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections

Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.